Transcription Factor ERG
Transcription Factor ERG
The ETS-related gene (ERG) is a member of the E-26 transformation-specific (ETS) family of transcription factors. The full-length ERG protein consists of 486 amino acids and has a molecular weight of 54 kDa. Initially, ERG is highly expressed in the embryonic mesoderm and endothelium. It regulates vascular stability by modulating Wnt/β-catenin signaling and angiopoietin-1-dependent Notch signaling. Additionally, ERG maintains vascular homeostasis by suppressing the expression of proinflammatory genes, such as ICAM1 and IL8, and by preventing endothelial-to-mesenchymal transition.
ERG is crucial for endothelial homeostasis and plays a vital role in the development of the vascular system, the urogenital tract, and bone. Furthermore, ERG possesses oncogenic potential and is implicated in Ewing’s sarcoma and leukemia[1][2][3].
ERG is crucial for endothelial homeostasis and plays a vital role in the development of the vascular system, the urogenital tract, and bone. Furthermore, ERG possesses oncogenic potential and is implicated in Ewing’s sarcoma and leukemia[1][2][3].
References:
- [1]. Adamo P, et al. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2016 Jan 28;35(4):403-14. [Content Brief]
- [2]. Kalna V, et al. The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program. Circ Res. 2019 Apr 26;124(9):1337-1349. [Content Brief]
- [3]. Shah AV, et al. Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG. Vascul Pharmacol. 2016 Nov;86:3-13. [Content Brief]
All Product Categories
-
Transcription Factor ERG Related Products (1)
Related Products (1)
-
PROTAC BRM/BRG1 degrader-3
0 ImagesCat. No.: HY-168251CAS No.: 2933125-05-2PROTAC BRM/BRG1 degrader-3 is a BRM/BRG1 PROTAC degrader, exhibiting a DC50 of less than 1 nM for BRM degradation and a DC50 of greater than 1 nM for BRG1 degradation in SW1573 cells. PROTAC BRM/BRG1 degrader-3 shows moderate inhibitory activity against CYP2D6 and hERG. PROTAC BRM/BRG1 degrader-3 inhibits cancer cell proliferation and tumor tissue growth, and exhibits favorable metabolic stability in liver microsomes. PROTAC BRM/BRG1 degrader-3 can be used in non-small cell lung cancer-related research.
